Skip to Content
Merck
All Photos(1)

Documents

C-093

Supelco

Cyclosporin A solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C62H111N11O12
CAS Number:
59865-13-3
Molecular Weight:
1202.61
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−70°C

SMILES string

O=C(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@H](C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N([C@H](C(C)C)C(N(C)[C@@H]([C@@H]([C@H](C)C/C=C/C)O)C1=O)=O)C)=O)=O)=O)=O)=O)CC(C)C)=O)=O)CN(C)C([C@@H](N1)CC)=O

InChI

1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50?,51+,52-/m1/s1

InChI key

PMATZTZNYRCHOR-VPYFBNRVSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

A Certified Spiking Solution® of an immunosuppressant and narrow therapeutic index drug used to prevent rejection in organ transplantation. This certified calibration material is suitable for critical quantitative applications in clinical and diagnostic testing such as therapeutic drug monitoring assays to ensure patients remain within the drug′s narrow therapeutic range.  The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as cyclosporin A, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Application


  • Novel IgE crosslinking-induced luciferase expression method using human-rat chimeric IgE receptor-carrying mast cells: This study leverages Cyclosporin A′s immunosuppressive properties to explore new methodologies for investigating allergic responses. By utilizing Cyclosporin A to modulate immune cell activity, researchers have developed an innovative in vitro assay that significantly enhances our understanding of immune mechanisms, demonstrating Cyclosporin A′s pivotal role in immunological research and its application in developing more effective allergy treatments (Akiyama H et al., 2024).

  • Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics: This review discusses the critical role of Cyclosporin A in the development of nanocarrier systems for targeted drug delivery, particularly for ocular applications. Cyclosporin A′s effectiveness in preventing transplant rejection and its properties as a calcineurin inhibitor make it an excellent candidate for incorporation into advanced drug delivery systems, enhancing therapeutic efficacy and reducing systemic side effects (Datta D et al., 2024).

  • A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: Demonstrating Cyclosporin A′s utility in enhancing the efficacy of controlled-release drug systems, this study details the use of Cyclosporin A with a novel xanthan gum-based platform. This research emphasizes Cyclosporin A′s role in the pharmaceutical industry, particularly in improving drug delivery mechanisms that can be crucial for treating chronic conditions (Signorini S et al., 2024).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jane Rasaiyaah et al.
Nature, 503(7476), 402-405 (2013-11-08)
Human immunodeficiency virus (HIV)-1 is able to replicate in primary human macrophages without stimulating innate immunity despite reverse transcription of genomic RNA into double-stranded DNA, an activity that might be expected to trigger innate pattern recognition receptors. We reasoned that
Tip W Loo et al.
Biochemistry, 52(41), 7167-7169 (2013-10-03)
There is no high-resolution crystal structure of the human P-glycoprotein (P-gp) drug pump. Homology models of human P-gp based on the crystal structures of mouse or Caenorhabditis elegans P-gps show large differences in the orientation of transmembrane segment 5 (TM5).
Koichi Watashi et al.
Hepatology (Baltimore, Md.), 59(5), 1726-1737 (2014-01-01)
Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other
David A Williams et al.
Pediatric blood & cancer, 61(5), 869-874 (2013-11-29)
Randomized clinical trials in pediatric aplastic anemia (AA) are rare and data to guide standards of care are scarce. Eighteen pediatric institutions formed the North American Pediatric Aplastic Anemia Consortium to foster collaborative studies in AA. The initial goal of
Derek J Hausenloy et al.
British journal of pharmacology, 165(5), 1235-1245 (2011-10-01)
Ischaemic heart disease (IHD) is the leading cause of death and disability worldwide. The pathophysiological effects of IHD on the heart most often result from the detrimental effects of acute ischaemia-reperfusion injury (IRI) on the myocardium. Therefore, novel therapeutic targets
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service